Cancer stem cells (CSCs) drive recurrence and resistance, evading standard therapies through iron-rich metabolism and ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

Researchers have identified RUNX1C, an RNA isoform that drives chemoresistance in acute myeloid leukemia (AML). The study, ...

Researchers have developed a novel cancer therapy using Salmonella typhimurium to deliver an oncolytic virus directly into ...

A novel mRNA-based vaccine encoding tumor-specific neoantigens significantly enhanced anti-PD-1 therapy in gastric cancer ...

FDA approved Papzimeos (zopapogene imadenovec), the first-in-class, non-replicating adenoviral vector-based immunotherapy, ...

New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB ...

Birelentinib has received FDA Fast Track Designation for relapsed/refractory chronic lymphocytic leukemia (CLL) or small ...

The FDA has granted accelerated approval to zongertinib for pretreated, HER2+ non-squamous NSC lung cancer, based on results ...

The FDA has granted accelerated approval to Modeyso™ (dordaviprone) as the first treatment for recurrent H3 K27M-mutant ...

The FDA has accepted Bristol Myers Squibb’s Priority Review application for Breyanzi® (lisocabtagene maraleucel) as a ...

CLD-201 (SuperNova), a novel stem cell–based oncolytic virus therapy, has received FDA Fast Track designation for soft tissue ...